These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 31969650)

  • 1. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.
    Kawakubo M; Tanaka M; Ochi K; Watanabe A; Saka-Tanaka M; Kanamori Y; Yoshioka N; Yamashita S; Goto M; Itoh M; Shirakawa I; Kanai S; Suzuki H; Sawada M; Ito A; Ishigami M; Fujishiro M; Arima H; Ogawa Y; Suganami T
    Sci Rep; 2020 Jan; 10(1):983. PubMed ID: 31969650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DPP-4 Inhibition with Anagliptin Reduces Lipotoxicity-Induced Insulin Resistance and Steatohepatitis in Male Mice.
    Sakai Y; Chen G; Ni Y; Zhuge F; Xu L; Nagata N; Kaneko S; Ota T; Nagashimada M
    Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32790863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
    Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
    Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed mice.
    Iwamoto Y; Kimura T; Dan K; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Shimoda M; Nogami Y; Shirakiya Y; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Obes Metab; 2024 Jun; 26(6):2339-2348. PubMed ID: 38504118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
    Nishina S; Yamauchi A; Kawaguchi T; Kaku K; Goto M; Sasaki K; Hara Y; Tomiyama Y; Kuribayashi F; Torimura T; Hino K
    Cell Mol Gastroenterol Hepatol; 2019; 7(1):115-134. PubMed ID: 30510994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
    Goto T; Itoh M; Suganami T; Kanai S; Shirakawa I; Sakai T; Asakawa M; Yoneyama T; Kai T; Ogawa Y
    Sci Rep; 2018 May; 8(1):8157. PubMed ID: 29802399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis.
    Wang X; Hausding M; Weng SY; Kim YO; Steven S; Klein T; Daiber A; Schuppan D
    Antioxid Redox Signal; 2018 Jan; 28(2):87-109. PubMed ID: 28635324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
    Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
    Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Branched-chain amino acids prevent hepatic fibrosis and development of hepatocellular carcinoma in a non-alcoholic steatohepatitis mouse model.
    Takegoshi K; Honda M; Okada H; Takabatake R; Matsuzawa-Nagata N; Campbell JS; Nishikawa M; Shimakami T; Shirasaki T; Sakai Y; Yamashita T; Takamura T; Tanaka T; Kaneko S
    Oncotarget; 2017 Mar; 8(11):18191-18205. PubMed ID: 28212548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of APD668, a G protein-coupled receptor 119 agonist with linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in a murine model of non-alcoholic steatohepatitis with diabetes.
    Bahirat UA; Talwar R; Shenoy RR; Nemmani KVS; Goel RN
    Med Mol Morphol; 2019 Mar; 52(1):36-43. PubMed ID: 29959534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.
    Shiba K; Tsuchiya K; Komiya C; Miyachi Y; Mori K; Shimazu N; Yamaguchi S; Ogasawara N; Katoh M; Itoh M; Suganami T; Ogawa Y
    Sci Rep; 2018 Feb; 8(1):2362. PubMed ID: 29402900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.
    Hirano T; Yamashita S; Takahashi M; Hashimoto H; Mori Y; Goto M
    Metabolism; 2016 Jun; 65(6):893-903. PubMed ID: 27173468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis.
    Itoh M; Suganami T; Nakagawa N; Tanaka M; Yamamoto Y; Kamei Y; Terai S; Sakaida I; Ogawa Y
    Am J Pathol; 2011 Nov; 179(5):2454-63. PubMed ID: 21906580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl Peptidase-4 Inhibitor Anagliptin Prevents Intracranial Aneurysm Growth by Suppressing Macrophage Infiltration and Activation.
    Ikedo T; Minami M; Kataoka H; Hayashi K; Nagata M; Fujikawa R; Higuchi S; Yasui M; Aoki T; Fukuda M; Yokode M; Miyamoto S
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28630262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice.
    Konuma K; Itoh M; Suganami T; Kanai S; Nakagawa N; Sakai T; Kawano H; Hara M; Kojima S; Izumi Y; Ogawa Y
    PLoS One; 2015; 10(3):e0121528. PubMed ID: 25816330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD11c+ resident macrophages drive hepatocyte death-triggered liver fibrosis in a murine model of nonalcoholic steatohepatitis.
    Itoh M; Suganami T; Kato H; Kanai S; Shirakawa I; Sakai T; Goto T; Asakawa M; Hidaka I; Sakugawa H; Ohnishi K; Komohara Y; Asano K; Sakaida I; Tanaka M; Ogawa Y
    JCI Insight; 2017 Nov; 2(22):. PubMed ID: 29202448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activation.
    Shinjo T; Nakatsu Y; Iwashita M; Sano T; Sakoda H; Ishihara H; Kushiyama A; Fujishiro M; Fukushima T; Tsuchiya Y; Kamata H; Nishimura F; Asano T
    Am J Physiol Endocrinol Metab; 2015 Aug; 309(3):E214-23. PubMed ID: 26015438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model.
    Yoshioka N; Tanaka M; Ochi K; Watanabe A; Ono K; Sawada M; Ogi T; Itoh M; Ito A; Shiraki Y; Enomoto A; Ishigami M; Fujishiro M; Ogawa Y; Suganami T
    Biomed Pharmacother; 2021 Aug; 140():111738. PubMed ID: 34029949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.